Rules-Based Medicine (RBM) is a biomarker testing laboratory delivering reproducible, quantitative, multiplexed immunoassay data. We use Multi-Analyte Profiles (MAP's) to measure up to hundreds of proteins in a very small sample in multiple species and sample types. Our MAPs provide a comprehensive and cost-effective evaluation of the protein expression patterns that are critical to applications such as drug safety and efficacy, disease diagnosis and disease modeling. RBM is CLIA certified and supports GLP studies.
HumanMAP | Version 1.6
Human Metabolic MAP | Version 1.0
RodentMAP | Version 2.0
Rat Metabolic MAP | Version 1.0
Rat Kidney MAP | Version 1.0
Custom MAP
TruCulture
Assay Development
Data Mining
Should I Submit Mouse Serum or Plasma to RBM for Rodent Multi-Analyte Profiling?
When discussing projects with our customers, they often ask, "Should we collect serum or plasma in our mouse study?"
Rules-Based Medicine Commercializes New Toxicity Biomarker Panel in Conjunction with FDA, EMEA, C-Path and PSTC
Rules-Based Medicine and Psynova Neurotech to Co-Develop Blood Test for Diagnosis of Schizophrenia
Rules-Based Medicine Partners with EMD to Develop and Distribute Multi-Analyte Kits
Rules-Based Medicine Raises $25 Million in Series A Funding
Rediscovering Biomarkers
Boston, MA — May 17-18, 2008
Biomarker World Congress
Philadelphia, PA — May 19-21, 2008
Targeted Designs for Clinical Trials
San Francisco, CA — May 23-24, 2008
Rediscovering Biomarkers
Boston MA — July 17-18, 2008
Targeted Immunotherapeutics and Vaccines
Boston, MA — August 12-15, 2008
Protein Discovery & Development
San Diego, CA — Sept. 8-9, 2008
|
Rules-Based Medicine, Inc. | 3300 Duval Road • Austin, TX 78759 • T: 866-RBM-MAPS • F: 512-835-4687 • E: info@rbmmaps.com |